(vianews) - ucb (ucb.br) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| ucb (ucb.br) | €168.85 | 0.84% | 2.67% |
| biomerieux (bim.pa) | €102.25 | 0.8% | 10.61% |
| sartorius sted bio (dim.pa) | €264.30 | 0.4% | 5.31% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ucb (ucb.br)
0.84% forward dividend yield and 2.67% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and fintepla to treat dravet syndrome. in addition, the company is involved in developing rozanolixizumab and zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat cdkl5 deficiency disorder; doxecitine for tk2 deficiency disorder; staccato alprazolam for stereotypical prolonged seizures; bepranemab to treat alzheimer's disease; minzasolmin and ucb0222 for parkinson's disease; and ucb1381 and ucb9741 for atropic dermatitis. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, and otsuka. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.23.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 137.28. meaning, the purchaser of the share is investing €137.28 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.67%.
more news about ucb.
2. biomerieux (bim.pa)
0.8% forward dividend yield and 10.61% return on equity
biomérieux s.a. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the americas, europe, the middle east, africa, and the asia pacific. the company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. it also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the biomérieux vision suite name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. the company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. biomérieux s.a. was formerly known as b-d mérieux. the company was founded in 1963 and is headquartered in marcy-l'étoile, france. biomérieux s.a. is a subsidiary of institut mérieux sa.
earnings per share
as for profitability, biomerieux has a trailing twelve months eps of €3.01.
pe ratio
biomerieux has a trailing twelve months price to earnings ratio of 33.97. meaning, the purchaser of the share is investing €33.97 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.61%.
volatility
biomerieux's last week, last month's, and last quarter's current intraday variation average was 0.14%, 0.20%, and 1.07%.
biomerieux's highest amplitude of average volatility was 1.45% (last week), 1.17% (last month), and 1.07% (last quarter).
more news about biomerieux.
3. sartorius sted bio (dim.pa)
0.4% forward dividend yield and 5.31% return on equity
sartorius stedim biotech s.a. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. the company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. it also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. in addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other dna/rna delivery reagents and plasmid dna. it serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. the company was incorporated in 1978 and is headquartered in aubagne, france. as of december 31, 2023, sartorius stedim biotech s.a. operates as a subsidiary of sartorius ag.
earnings per share
as for profitability, sartorius sted bio has a trailing twelve months eps of €3.36.
pe ratio
sartorius sted bio has a trailing twelve months price to earnings ratio of 78.66. meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.31%.
more news about sartorius sted bio.